Genmab — December 2024
-
Genmab eller anden partner må kun markedsføre ergo til dara resistente patienter inden for MM og amyloidosis
-
Så det er vist meget få patienter de må markedsføre ergo til
-
Ja haha erzo naturligvis
-
Ja tak. Jeg fik også lige fundet pressemeddelelsen herom fra juni 2019 - https://ir.genmab.com/news-releases/news-release-details/genmab-signs-agreement-janssen-next-generation-cd38-antibody/
-
Godmorgen
-
Jeg synes det er lidt sært at man ikke oplyser når datasættet sendes til Janssen. Jeg kan ikke finde der hvor Genmab oplyser om de 60 dages svarfrist. Er der nogen der ved det?
-
from Genmab A/S Virtual R&D Update and ASH Data Review
Dec 11, 2024: . Let's start with HexaBody-CD38.
Here, I will reiterate what I said already during our third quarter results call. We are well on track to submit a data package to J&J by the end of this month. The optimum period of 60 days is expected to start in the beginning of January, which means that we anticipate a decision from J&J no later than the first quarter of 2025. -
-
European Commission approves RYBREVANT
▼ (amivantamab) in combination with LAZCLUZE▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer -MARIPOSA https://www.globenewswire.com/news-release/2024/12/30/3002463/0/en/European-Commission-approves-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind